Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Down 55.6% in January

Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 182 shares, a drop of 55.6% from the December 31st total of 410 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 905 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 905 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company’s shares are short sold.

Mosaic ImmunoEngineering Trading Down 13.8%

Mosaic ImmunoEngineering stock opened at $0.60 on Friday. The company has a market cap of $4.36 million, a PE ratio of -6.69 and a beta of -0.82. Mosaic ImmunoEngineering has a 1 year low of $0.25 and a 1 year high of $1.05. The company’s 50-day moving average is $0.50 and its two-hundred day moving average is $0.56.

Mosaic ImmunoEngineering (OTCMKTS:CPMV) last posted its quarterly earnings results on Wednesday, November 19th. The company reported ($0.02) earnings per share for the quarter.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.